BANGALORE, Dec 5 (Reuters) - Shares of Targanta Therapeutics Corp rose as much as 86 percent on Friday, ahead of a key regulatory meeting on Monday that would decide the fate of the company's experimental skin-infection antibiotic, oritavancin.
'There is a little bit of speculation that at the current price, downside is limited, but there is a lot of upside if the Food and Drug Administration does give them a positive (nod),' Cowen & Co analyst Ian Sanderson told Reuters.
The company had in September submitted oritavancin for approval as a treatment for complicated skin infections from a variety Continue reading